Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis

Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved for adult patients with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA) Approvals for both indications based on efficacy and safety outcomes shown across four P... Biopharmaceuticals, FDANovartis, Cosentyx, secukinumab, psoriasis, ankylosing spondylitis, arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news